About: Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection
Creator	Carnahan, Robert Diamond, Michael Van Hoeven, Neal Reed, Steven Crowe, James Thackray, Larissa Archer, Jacob Coler, Rhea Erasmus, Jesse Khandhar, Amit Bombardi, Robin Durnell, Lorellin Fuerte-Stone, Jasmine Govero, Jennifer Granger, Brian Tan, Qing Voigt, Emily
Source	Medline; PMC
abstract	Monoclonal antibody (mAb) therapeutics are an effective modality for the treatment of infectious, autoimmune, and cancer-related diseases. However, the discovery, development, and manufacturing processes are complex, resource-consuming activities that preclude the rapid deployment of mAbs in outbreaks of emerging infectious diseases. Given recent advances in nucleic acid delivery technology, it is now possible to deliver exogenous mRNA encoding mAbs for in situ expression following intravenous (i.v.) infusion of lipid nanoparticle-encapsulated mRNA. However, the requirement for i.v. administration limits the application to settings where infusion is an option, increasing the cost of treatment. As an alternative strategy, and to enable intramuscular (IM) administration of mRNA-encoded mAbs, we describe a nanostructured lipid carrier for delivery of an alphavirus replicon encoding a previously described highly neutralizing human mAb, ZIKV-117. Using a lethal Zika virus challenge model in mice, our studies show robust protection following alphavirus-driven expression of ZIKV-117 mRNA when given by IM administration as pre-exposure prophylaxis or post-exposure therapy.
has issue date	2020-06-18(xsd:dateTime)
bibo:doi	10.1016/j.omtm.2020.06.011
bibo:pmid	32695842
has license	cc-by-nc-nd
sha1sum (hex)	b759d03cdb5952df3790d8b2156a6b5708daa586
schema:url	https://doi.org/10.1016/j.omtm.2020.06.011
resource representing a document's title	Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection
has PubMed Central identifier	PMC7363633
has PubMed identifier	32695842
schema:publication	Mol Ther Methods Clin Dev
resource representing a document's body	covid:b759d03cdb5952df3790d8b2156a6b5708daa586#body_text
is schema:about of	named entity 'lipid' named entity 'expression' named entity 'situ' named entity 'autoimmune' named entity 'settings' named entity 'mice' named entity 'Encoding' named entity 'discovery' named entity 'enable' named entity 'deployment' named entity 'activities' named entity 'infusion' named entity 'mAbs' named entity 'mice' named entity 'nucleic acid' named entity 'ZIKV' named entity 'alphavirus' named entity 'lipid' named entity 'alphavirus' named entity 'mAb' named entity 'mRNA' named entity 'infusion' named entity 'post-exposure' named entity 'prophylaxis' named entity 'RNA' named entity 'Infection' named entity 'Replicon' named entity 'Zika Virus' named entity 'serum' named entity 'liver' named entity 'antibody' named entity 'recombinant' named entity 'ZIKV' named entity 'ZIKV' named entity 'ORF' named entity 'intramuscular' named entity 'mice' named entity 'plasmid DNA' named entity 'restriction digest' named entity 'inoculation' named entity 'mice' named entity 'New England Biolabs' named entity 'IFNAR1' named entity 'electroporation' named entity 'cloned' named entity 'NotI' named entity 'EMCV' named entity 'mycoplasma' named entity 'antibody' named entity 'substrate' named entity 'Institutional Animal Care and Use Committee' named entity 'epidemics' named entity 'ZIKV' named entity 'protein' named entity 'IgG' named entity 'ZIKV' named entity 'Virus' named entity 'mRNA' named entity 'supernatant' named entity 'pseudouridine' named entity 'binding immunoglobulin protein' named entity 'serum concentrations' named entity 'epidemics' named entity 'mRNAs' named entity 'Virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software